BIODESIX, INC. (BDSX) Free cash flow
- Free cash flow · 12 months (USD): Value $-20.24M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -19.67%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-20.24M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-19.83M − $412.00K ≈ $-20.24M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -19.67% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-20.24M ÷ $102.94M × 100 ≈ -19.67% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-19.83M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.71× | Operating cash flow / net income. Period ending 2026-06-30. $-19.83M ÷ $-27.77M ≈ 0.71× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -19.83M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 412.00K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -20.24M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 102.94M USD | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -27.77M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-20.24M | (m) | $-19.83M | $412.00K | (m) | $102.94M | (m) | $-27.77M | (m) | (m) | -19.67% | 0.71× |
| 2026-03-31 | $-25.10M | (m) | $-24.84M | $266.00K | (m) | $96.10M | (m) | $-31.96M | (m) | (m) | -26.12% | 0.78× |
| 2025-12-31 | $-23.53M | (m) | $-23.27M | $259.00K | (m) | $88.50M | (m) | $-35.27M | (m) | (m) | -26.59% | 0.66× |
| 2025-09-30 | $-29.16M | (m) | $-28.14M | $1.01M | (m) | $80.17M | (m) | $-39.54M | (m) | (m) | -36.37% | 0.71× |
| 2025-06-30 | $-31.13M | (m) | $-29.94M | $1.20M | (m) | $76.56M | (m) | $-41.08M | (m) | (m) | -40.67% | 0.73× |
| 2025-03-31 | $-45.01M | (m) | $-41.94M | $3.07M | (m) | $74.46M | (m) | $-40.42M | (m) | (m) | -60.45% | 1.04× |
| 2024-12-31 | $-51.88M | (m) | $-48.65M | $3.23M | (m) | $71.32M | (m) | $-42.93M | (m) | (m) | -72.74% | 1.13× |
| 2024-09-30 | $-62.21M | (m) | $-56.84M | $5.38M | (m) | $65.56M | (m) | $-43.82M | (m) | (m) | -94.89% | 1.30× |
| 2024-06-30 | $-60.99M | (m) | $-50.00M | $10.99M | (m) | $60.90M | (m) | $-44.51M | (m) | (m) | -100.14% | 1.12× |
| 2024-03-31 | $-45.97M | (m) | $-30.50M | $15.48M | (m) | $54.85M | (m) | $-47.06M | (m) | (m) | -83.82% | 0.65× |
| 2023-12-31 | $-45.79M | (m) | $-22.87M | $22.92M | (m) | $49.09M | (m) | $-52.15M | (m) | (m) | -93.28% | 0.44× |
| 2023-09-30 | $-44.40M | (m) | $-22.54M | $21.86M | (m) | $44.03M | (m) | $-63.34M | (m) | (m) | -100.85% | 0.36× |
| 2023-06-30 | $-45.83M | (m) | $-29.03M | $16.80M | (m) | $41.64M | (m) | $-66.09M | (m) | (m) | -110.05% | 0.44× |
| 2023-03-31 | $-50.27M | (m) | $-39.56M | $10.71M | (m) | $40.72M | (m) | $-68.56M | (m) | (m) | -123.46% | 0.58× |
| 2022-12-31 | $-48.27M | (m) | $-44.97M | $3.30M | (m) | $38.21M | (m) | $-65.45M | (m) | (m) | -126.32% | 0.69× |
| 2022-09-30 | $-45.12M | (m) | $-43.22M | $1.90M | (m) | $35.83M | (m) | $-58.39M | (m) | (m) | -125.93% | 0.74× |
| 2022-06-30 | $-42.77M | (m) | $-40.68M | $2.08M | (m) | $31.25M | (m) | $-56.21M | (m) | (m) | -136.83% | 0.72× |
| 2022-03-31 | $-32.03M | (m) | $-30.00M | $2.04M | (m) | $32.19M | (m) | $-51.78M | (m) | (m) | -99.52% | 0.58× |
| 2021-12-31 | $-30.46M | (m) | $-28.22M | $2.24M | (m) | $54.51M | (m) | $-43.16M | (m) | (m) | -55.89% | 0.65× |
| 2021-09-30 | $-28.95M | (m) | $-26.78M | $2.17M | (m) | $74.31M | (m) | $-34.41M | (m) | (m) | -38.96% | 0.78× |
| 2021-06-30 | $-25.22M | (m) | $-22.76M | $2.46M | (m) | $76.97M | (m) | $-31.74M | (m) | (m) | -32.77% | 0.72× |
| 2021-03-31 | $-30.47M | (m) | $-28.16M | $2.31M | (m) | $69.33M | (m) | $-28.61M | (m) | (m) | -43.95% | 0.98× |
| 2020-12-31 | $-23.31M | (m) | $-21.37M | $1.95M | (m) | $45.56M | (m) | $-31.35M | (m) | (m) | -51.17% | 0.68× |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-32.69M | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-23.04M | (m) | $-21.73M | $1.31M | (m) | $24.55M | (m) | $-30.73M | (m) | (m) | -93.83% | 0.71× |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |